nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—seminal vesicle—rectum cancer	0.0692	0.0814	CbGeAlD
Everolimus—FKBP1A—seminal vesicle—rectum cancer	0.0623	0.0732	CbGeAlD
Everolimus—MTOR—epithelium—rectum cancer	0.0601	0.0707	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—rectum cancer	0.0579	0.0681	CbGeAlD
Everolimus—MTOR—renal system—rectum cancer	0.0558	0.0656	CbGeAlD
Everolimus—FKBP1A—epithelium—rectum cancer	0.0541	0.0636	CbGeAlD
Everolimus—MTOR—mammalian vulva—rectum cancer	0.0522	0.0613	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—rectum cancer	0.0521	0.0613	CbGeAlD
Everolimus—FKBP1A—renal system—rectum cancer	0.0502	0.059	CbGeAlD
Everolimus—FKBP1A—urethra—rectum cancer	0.0493	0.0579	CbGeAlD
Everolimus—FKBP1A—mammalian vulva—rectum cancer	0.0469	0.0552	CbGeAlD
Everolimus—MTOR—female reproductive system—rectum cancer	0.0447	0.0525	CbGeAlD
Everolimus—MTOR—vagina—rectum cancer	0.0404	0.0475	CbGeAlD
Everolimus—FKBP1A—female reproductive system—rectum cancer	0.0402	0.0472	CbGeAlD
Everolimus—FKBP1A—vagina—rectum cancer	0.0363	0.0427	CbGeAlD
Everolimus—MTOR—lymph node—rectum cancer	0.0261	0.0307	CbGeAlD
Everolimus—FKBP1A—lymph node—rectum cancer	0.0235	0.0276	CbGeAlD
Everolimus—CYP3A4—renal system—rectum cancer	0.0164	0.0193	CbGeAlD
Everolimus—CYP3A4—female reproductive system—rectum cancer	0.0131	0.0154	CbGeAlD
Everolimus—MTOR—EGFR-dependent Endothelin signaling events—HRAS—rectum cancer	0.00682	0.0457	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—NRAS—rectum cancer	0.00356	0.0239	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.00332	0.0223	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—KRAS—rectum cancer	0.00306	0.0205	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—NRAS—rectum cancer	0.00295	0.0197	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—HRAS—rectum cancer	0.00289	0.0194	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—NRAS—rectum cancer	0.00277	0.0186	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—HRAS—rectum cancer	0.0026	0.0175	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—KRAS—rectum cancer	0.00254	0.017	CbGpPWpGaD
Everolimus—MTOR—Alpha 6 Beta 4 signaling pathway—HRAS—rectum cancer	0.00241	0.0162	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—KRAS—rectum cancer	0.00239	0.016	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—HRAS—rectum cancer	0.00216	0.0144	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—rectum cancer	0.00204	0.0137	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—rectum cancer	0.00203	0.0136	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—KRAS—rectum cancer	0.00191	0.0128	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—NRAS—rectum cancer	0.00189	0.0127	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—rectum cancer	0.0017	0.0114	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—rectum cancer	0.00165	0.0111	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—KRAS—rectum cancer	0.00163	0.0109	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—HRAS—rectum cancer	0.00163	0.0109	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—rectum cancer	0.00162	0.0108	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—NRAS—rectum cancer	0.00155	0.0104	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—NRAS—rectum cancer	0.00151	0.0101	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—rectum cancer	0.00149	0.01	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—rectum cancer	0.00147	0.00983	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—NRAS—rectum cancer	0.00145	0.00973	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—NRAS—rectum cancer	0.00145	0.00973	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—rectum cancer	0.0014	0.0094	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—rectum cancer	0.0014	0.00937	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—HRAS—rectum cancer	0.00139	0.00929	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—HRAS—rectum cancer	0.00139	0.00929	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—KRAS—rectum cancer	0.00133	0.00893	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—HRAS—rectum cancer	0.00132	0.00886	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—NRAS—rectum cancer	0.00131	0.00876	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—KRAS—rectum cancer	0.0013	0.00868	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—rectum cancer	0.00129	0.00863	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—rectum cancer	0.00128	0.0086	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—HRAS—rectum cancer	0.00125	0.00839	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—KRAS—rectum cancer	0.00125	0.00838	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—KRAS—rectum cancer	0.00125	0.00838	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.00124	0.0083	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NRAS—rectum cancer	0.00122	0.00814	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—NRAS—rectum cancer	0.00121	0.00809	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—rectum cancer	0.00119	0.00796	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—HRAS—rectum cancer	0.00113	0.00759	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—KRAS—rectum cancer	0.00112	0.00754	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—rectum cancer	0.00111	0.00742	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.0011	0.00738	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—rectum cancer	0.0011	0.00738	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—rectum cancer	0.00109	0.00731	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—rectum cancer	0.00106	0.00712	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—rectum cancer	0.00106	0.00712	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—KRAS—rectum cancer	0.00105	0.00701	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—KRAS—rectum cancer	0.00104	0.00696	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—rectum cancer	0.00103	0.00692	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—rectum cancer	0.001	0.0067	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—rectum cancer	0.000988	0.00662	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—NRAS—rectum cancer	0.000972	0.00651	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—rectum cancer	0.000956	0.00641	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—rectum cancer	0.000956	0.00641	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—rectum cancer	0.000942	0.00631	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—NRAS—rectum cancer	0.000928	0.00622	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—NRAS—rectum cancer	0.000924	0.00619	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—NRAS—rectum cancer	0.000919	0.00616	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—rectum cancer	0.000915	0.00613	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000902	0.00604	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—rectum cancer	0.000889	0.00596	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—rectum cancer	0.000889	0.00595	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—rectum cancer	0.000883	0.00592	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.000861	0.00577	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—rectum cancer	0.000861	0.00577	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—rectum cancer	0.000861	0.00577	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—rectum cancer	0.000853	0.00572	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.00085	0.0057	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.000845	0.00566	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—rectum cancer	0.000842	0.00564	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—rectum cancer	0.000841	0.00564	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—rectum cancer	0.000837	0.00561	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KRAS—rectum cancer	0.000799	0.00535	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—rectum cancer	0.000797	0.00534	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—rectum cancer	0.000795	0.00533	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—rectum cancer	0.000795	0.00533	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KRAS—rectum cancer	0.000791	0.0053	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—rectum cancer	0.000787	0.00528	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000776	0.0052	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.000762	0.00511	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—rectum cancer	0.000755	0.00506	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—rectum cancer	0.000748	0.00501	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—rectum cancer	0.000743	0.00498	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000741	0.00496	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—rectum cancer	0.000741	0.00496	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—rectum cancer	0.000741	0.00496	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KRAS—rectum cancer	0.000734	0.00492	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000728	0.00488	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KRAS—rectum cancer	0.000724	0.00485	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000723	0.00484	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—rectum cancer	0.000711	0.00477	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KRAS—rectum cancer	0.000686	0.00459	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—rectum cancer	0.000683	0.00457	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—rectum cancer	0.000679	0.00455	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—rectum cancer	0.000676	0.00453	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	0.000676	0.00453	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—rectum cancer	0.000673	0.00451	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—HRAS—rectum cancer	0.000669	0.00448	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.00066	0.00442	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000656	0.0044	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—rectum cancer	0.00063	0.00422	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—rectum cancer	0.00063	0.00422	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.00063	0.00422	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—rectum cancer	0.000624	0.00418	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000619	0.00414	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—rectum cancer	0.000616	0.00413	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NRAS—rectum cancer	0.000586	0.00393	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—rectum cancer	0.000583	0.0039	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000558	0.00374	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—rectum cancer	0.000505	0.00338	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—rectum cancer	0.000478	0.0032	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—rectum cancer	0.000429	0.00287	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—rectum cancer	0.000334	0.00224	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—rectum cancer	0.000321	0.00215	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—rectum cancer	0.00032	0.00214	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—rectum cancer	0.000288	0.00193	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—rectum cancer	0.000276	0.00185	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—rectum cancer	0.000275	0.00184	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—rectum cancer	0.000245	0.00164	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—rectum cancer	0.000235	0.00157	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—rectum cancer	0.000234	0.00157	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—rectum cancer	0.000224	0.0015	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—rectum cancer	0.000195	0.00131	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—rectum cancer	0.000193	0.00129	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—rectum cancer	0.00018	0.0012	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—rectum cancer	0.000171	0.00115	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—rectum cancer	0.000168	0.00112	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—rectum cancer	0.000164	0.0011	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—rectum cancer	0.000155	0.00104	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—rectum cancer	0.000142	0.000955	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—rectum cancer	0.000132	0.000882	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—rectum cancer	0.000126	0.000844	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—rectum cancer	0.000108	0.000726	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—rectum cancer	9.63e-05	0.000645	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—rectum cancer	9.21e-05	0.000617	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—rectum cancer	9.21e-05	0.000617	CbGpPWpGaD
